EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma

Lisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A Goldstein, Joshua Veatch, Joel Ho und 3 weitere

Cancer Immunology, Immunotherapy · 2023-11 · 72 (11) · 3839-3850

DOI: 10.1007/s00262-023-03539-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 21.09.2023. Verfasst von Lisa May Ling Tachiki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. ltachiki@uw.edu. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Melanoma, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Kuni Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Optimal duration of treatment (DoT) with immune checkpoint inhibitors (ICI) in metastatic cancers remains unclear. Many patients, especially those without radiologic complete remission, develop progressive disease after ICI discontinuation. Extending DoT with ICI may potentially improve efficacy outcomes but presents major logistical and cost challenges with standard frequency dosing (SFD). Receptor occupancy data supports reduced frequency dosing (RFD) of anti-PD-1 antibodies, which may represent a more practical and economically viable option to extend DoT.

Methods

We conducted a retrospective study of patients with metastatic melanoma and Merkel cell carcinoma (MCC), who received ICI at RFD administered every 3 months, after initial disease control at SFD. We evaluated efficacy, safety, and cost-savings of the RFD approach in this cohort.

Results

Between 2014 and 2021, 23 patients with advanced melanoma (N = 18) or MCC (N = 5) received anti-PD-1 therapy at RFD. Median DoT was 1.1 years at SFD and 1.2 years at RFD. The 3 year PFS after start of RFD was 73% in melanoma and 100% in MCC patients, which compare favorably to historical control rates. In the subset of 15 patients who received at least 2 years of therapy, total savings amounted to $1.1 million in drug costs and 384 h saved despite the extended DoT (median 3.4 years), as compared to the calculated cost of 2 years at SFD.

Conclusions

ICI administration at RFD can allow extension of treatment duration, while preserving efficacy and reducing logistical and financial burden. RFD approach deserves further exploration in prospective clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellMelanomaSkin NeoplasmsImmune Checkpoint InhibitorsHumansDuration of TherapyProspective StudiesRetrospective Studies

Stichwörter der Autor:innen

Drug costsImmunotherapyMelanomaMerkel cell carcinomaNivolumabPembrolizumab

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. ltachiki@uw.edu.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ltachiki@uw.edu.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
  • Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA.
  • Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Kuni Foundation
  • University of Washington
  • National Institutes of Health/NCI Cancer Center Support Grant
  • Kelsey Dickson Merkel Cell Carcinoma Fund

Zitieren

APA

Tachiki, L. M. L., Hippe, D. S., Williams Silva, K., Hall, E. T., McCamy, W., Fritzsche, D., Perdue, A., Majovski, J., Pulliam, T., Goldstein, D. A., Veatch, J., Ho, J., Nghiem, P. T., Thompson, J. A., & Bhatia, S. (2023). Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunology, Immunotherapy, 72(11), 3839-3850. https://doi.org/10.1007/s00262-023-03539-8

Vancouver

Tachiki LML, Hippe DS, Williams Silva K, Hall ET, McCamy W, Fritzsche D, et al. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunology, Immunotherapy. 2023;72(11):3839-3850. doi:10.1007/s00262-023-03539-8

BibTeX
@article{Tachiki2023,
  author = {Tachiki, Lisa May Ling and Hippe, Daniel S and Williams Silva, Karly and Hall, Evan Thomas and McCamy, William and Fritzsche, Dane and Perdue, Andrea and Majovski, Julia and Pulliam, Thomas and Goldstein, Daniel A and Veatch, Joshua and Ho, Joel and Nghiem, Paul T and Thompson, John A and Bhatia, Shailender},
  title = {Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {11},
  pages = {3839--3850},
  doi = {10.1007/s00262-023-03539-8}
}
Kostenlos starten →